Table 1.
Peptide drugs approved since 2000, with their targets and indications
| Target name | Peptide name | First approval | Approved indication(s) |
|---|---|---|---|
| GLP-1 receptor | Exenatide462 | 2005 | Indicated for Type 2 Diabetes Mellitus |
| Liraglutide463 | 2009 | ||
| Lixisenatide464 | 2013 | ||
| Albiglutide465 | 2014 | ||
| Dulaglutide466 | 2014 | ||
| Semaglutide467 | 2017 | ||
| GLP-2 receptor | Teduglutide468 | 2012 | Treatment of Short bowel syndrome and malabsorption |
| GC-C receptor | Linaclotide469 | 2012 | Treatment of irritable bowel syndrome (IBS) with constipation and chronic idiopathic constipation |
| Calcitonin receptor | Pramlintide470 | 2005 | Treatment of Type 1 and Type 2 Diabetes Mellitus |
| GnRH receptor | Abarelix471 | 2003 | Treatment of advanced prostate cancer |
| Degarelix472 | 2008 | ||
| Binding to active site of the 20S proteasome | Carfilzomib473 | 2012 | Treatment of multiple myeloma |
| NOD2 protein | Mifamurtide474 | 2009 | Treatment of high-grade, resectable, non-metastatic osteosarcoma |
| VIP1 receptor | Aviptadil475 | 2000 | Treatment of erectile dysfunction |
| OT receptor | Atosiban476 | 2000 | Indicated for use in delaying imminent pre-term birth |
| Carbetocin476 | 2001 | Used for postpartum hemorrhage | |
| TRH receptor | Taltirelin477 | 2000 | Spinocerebellar degeneration |
| MC receptors | Bremelanotide478 | 2019 | Indicated for hypoactive sexual desire disorder |
| PTH1 receptor | Teriparatide479 | 2002 | Treatment of osteoporosis |
| Abaloparatide480 | 2017 | ||
| Guanylate cyclase C | Plecanatide481 | 2017 | Treatment of chronic idiopathic constipation |
| NPR-A | Nesiritide482 | 2001 | Treatment of acute decompensated heart failure |
| AT1 receptor | Angiotensin II483 | 2017 | Indicated for sepsis and septic Shock |
| Beta2-receptor | Icatibant484 | 2008 | Approved for use in acute attacks of hereditary angioedema |
| gp41 | Enfuvirtide485 | 2003 | Used in combination therapy for the treatment of HIV-1 |
| GHRH receptor | Tesamorelin486 | 2010 | Reduction of HIV lipodystrophy |
| N-type calcium channels | Ziconotide487 | 2004 | Management of severe chronic pain |
| Thrombopoietin receptor | Romiplostim488 | 2008 | Treatment of chronic immune thrombocytopenic purpura |
| Human erythropoietin receptor | Peginesatide489 | 2012 | Treatment of anemia associated with chronic kidney disease |
| Pulmonary surfactant | Lucinactant490 | 2012 | Prevention of respiratory distress syndrome |
| CaSR | Etelcalcetide491 | 2016 | Indicated for secondary hyperparathyroidism |
| MC1 receptor | Afamelanotide492 | 2014 | Prevention of phototoxicity |
| Somatostatin receptors | Pasireotide493 | 2012 | Treatment of Cushing’s disease |
| Lutetium Lu 177 dotatate494,495 | 2018 | Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors | |
| Edotreotide gallium Ga-68496,497 | 2019 | Indicated for diagnose somatostatin receptor positive neuroendocrine tumors | |
| Melanocortin-4 receptor | Setmelanotide498,499 | 2020 | Indicated for chronic weight management of obesity |